Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Lytica Therapeutics Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 1 distinct art unit. MARTINEZ, TARA L is the busiest examiner with 2 pending actions. This concentration means that a majority of the current pending workload is under the review of a single examiner.
The portfolio shows a concentration of workload, as 2 of the 3 pending office actions are handled by examiner MARTINEZ, TARA L. All 3 actions are being prosecuted within a single distinct art unit, focusing the company's biotech matters under a limited number of USPTO personnel. This focus within 1 art unit and 2 examiners may allow for a more centralized prosecution strategy compared to portfolios spread across more units. However, with MARTINEZ, TARA L handling 2 of the 3 actions, the outcome of a significant portion of the pending portfolio depends on the findings of this specific examiner. The 3 pending office actions represent the entirety of the company's active engagement in this art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTINEZ, TARA L | 2 | 62.7% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289103 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | MARTINEZ, TARA L | — |
| 18289050 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | MARTINEZ, TARA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289103 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | MARTINEZ, TARA L | — |
| 18289050 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | MARTINEZ, TARA L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289103 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | MARTINEZ, TARA L | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18289050 | STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF | MARTINEZ, TARA L | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLytica Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tara L Martinez has the most, with 2 of Lytica Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
